Financial HealthThe company has no debt and enough capital to last into the third quarter of 2025 based on current cash burn assumptions.
Regulatory ApprovalNXL has received approval from the FDA for pilot trial designs for the treatment of insomnia with its Gen-3 device, paving the way for market entry.
Technology And InnovationNexalin Technology, Inc. is launching a home device designed to treat mental health disorders with a focus on insomnia, potentially transforming the market.